

Transcriptome analysis and in vivo activity of Fluvastatin versus Zoledronic acid in a murine breast cancer metastasis model.

Nadejda Vintonenko, Jean-Philippe Jais, Nadim Kassis , Mohamed Abdelkarim, Gerard-Yves Perret, Marc Lecouvey , Michel Crepin , Mélanie Di Benedetto

Molecular pharmacol

Supplemental Figure S1.




Figure S1. Effect of Fluva (low concentration) and Zol combination *in vivo*.

As described in Fig. 2 and 6, mice were treated upon detection of established metastasis (denoted as Day 0) with Zol (at 100µg/kg three times a week), Fluva (at 1 mg/kg daily), their combination (100µg/kg Zol thrice a week + 1 mg/kg Fluva daily), or PBS (daily for control group) during 3 weeks. A, Plot of bioluminescent signal; each point represents a mean (±SEM) signal of eight mice for Control, Fluva 1mg/kg, or combination of 100 µg/kg Zol with 1mg/kg Fluva . B, Kaplan-Meyer survival curves for Control and treated mice (median survival of 21 days for Control, and 33, 21, and 34.5 days for Zol, Fluva, and Zol/Fluva combination respectively).